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Introduction
Prostate cancer is the most prevalent cancer in men in Western societies (1) . Although the majority of prostate cancers behave in an indolent manner, a small subset is highly aggressive and requires extensive treatment (2, 3) . Established pre-operative prognostic parameters are limited to Gleason grade and tumor extent on biopsies, prostate-specific antigen (PSA) and clinical stage. These data are statistically powerful but often insufficient for optimal individual treatment decisions. It is thus hoped that a better understanding of disease biology will eventually lead to the identification of clinically applicable molecular markers that enable a more reliable prediction of prostate cancer aggressiveness. Proteins that affect genomic stability play an important role for cancer development (4) . Defects in DNA mismatch repair (MMR) proteins result in an accumulation of mutations that are associated with malignant transformation (5, 6) . Six MMR proteins are required for proper nucleotide MMR: MSH2, MLH1, PMS1, PMS2, MSH6 and MLH3. These proteins function coordinately within biochemical complexes to recognize and repair single base-base mismatches or defective insertion-deletion loops (7) . Although the role of MMR proteins has been intensively studied in colorectal cancer (8, 9) , their contribution to tumors of different origin is less well-characterized. Several lines of evidence suggest that MMR deficiency is linked to an aggressive form of prostate cancer. Only recently, a hypermutated subtype of advanced prostate cancer was described, which is associated with mutations, structural rearrangements and loss of expression of the MMR genes MSH2 and MSH6 (10, 11) . In addition, several studies reported altered expression of MMR genes including MLH1, MSH2, MSH6 and PMS2 in cohorts of 11-166 prostate cancers (12) (13) (14) (15) (16) . However, the clinical significance of these alterations remains unclear. Some studies reported associations between loss of MMR gene expression and adverse prostate cancer features (12, 14) , whereas others suggested a link between MMR gene overexpression and prostate cancer development (13) or poor patient prognosis (15, 16) . This study was undertaken to clarify the clinical significance of expression alterations of the MMR genes MSH6, PMS2 and MLH1 in prostate cancer. We selected these genes because they are frequently altered and part of the MMR gene set routinely analyzed in colorectal cancer (17) . Using immunohistochemistry (IHC), a tissue microarray (TMA) containing 11 152 prostate cancer specimens was analyzed, for which follow-up information and attached molecular data on genomic alterations, such as TMPRSS2:ERG fusion and characteristic genomic deletions, were available.
Materials and methods

Patients
Radical prostatectomy specimens were available from 11 152 patients, undergoing surgery between 1992 and 2011 at the Department of Urology and the Martini Clinics at the University Medical Center HamburgEppendorf. Follow-up data were available for 9695 patients with a median follow-up of 50.0 months (average 62.9 months, range: 1-264 months; Supplementary Table 1, available at Carcinogenesis Online). The follow-up data were obtained from the Martini-Klinik database, which was initiated in 1992 (H. Huland) with yearly patient reported outcome measurement and a typical annual follow-up rate of more than 50%. PSA values were measured following surgery, and recurrence was defined as a post-operative PSA of 0.2 ng/ml and increasing at first of appearance. All prostate specimens were analyzed according to a standard procedure, including complete embedding of the entire prostate for histological analysis (18) . The TMA manufacturing process was earlier described in detail (19) . In short, one 0.6 mm core was taken from a representative tissue block from each patient. The tissues were distributed among 24 
Statistics
Statistical calculations were performed with JMP® 9 software (SAS Institute, Cary, NC). Contingency tables and the χ 2 test were performed to search for associations between molecular parameters and tumor phenotype. Survival curves were calculated according to Kaplan-Meier estimator. The log-rank test was applied to detect significant survival differences between groups. COX proportional hazards regression analysis was performed to test the statistical independence and significance between pathological, molecular and clinical variables.
Results
Technical issues
IHC analysis was successful for MSH6 in 6831 (61.2%), for PMS2 in 7123 (63.8%) and for MLH1 in 7275 (65.3%) of our 11 165 arrayed prostate cancers. Non-informative cases were due to a complete lack of tissue in the TMA section or absence of unequivocal cancer cells on individual TMA spots.
MSH6, PMS2, MLH1 expression in normal and cancerous prostate
Normal prostate epithelium showed variable levels of nuclear staining of MSH6, PMS2 and MLH1 in basal and luminal cells. Staining intensity ranged from negative to moderate in n = 20 samples and was typically (in about 2 of the 3 samples) negative to weak. Figure 2 . pT, pathological tumor stage; GL, Gleason grade; pN, pathological lymph node stage; R, stage of the resection margin; P, χ 2 P value (*P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001).
Association with prostate cancer phenotype
Because of the prominent MMR gene expression differences between ERG-negative and ERG-positive cancers, we studied the relationship between MMR gene expression and prostate cancer phenotype separately in the two cancer subsets defined by the presence or absence of ERG. It showed that high expression levels of MSH6, PMS2 and MLH1-analyzed either separately or in combination-were significantly linked to advanced pathological tumor stage, high Gleason grade and lymph node metastasis in both subsets, although these association were much stronger in ERG-negative (P < 0.0015 for all parameters) as compared with ERG-positive cancers where only the association to Gleason grade remained highly significant (P < 0.0001). All results are summarized in Table 1 .
Prognostic relevance
Follow-up data were available for 5917, 6197 and 6326 patients with interpretable MSH6, PMS2 and MLH1 data. Strong MSH6, PMS2 and MLH1 expression was related to early biochemical recurrence in univariate analysis of all cancers (P < 0.0001 each). This held also true if the three genes were combined according to the 'MMR score': score A cancers, characterized by strong expression of all three MMR genes, had the worst prognosis, whereas score D cancers-showing not more than weak staining of all three proteins-had the best outcome. As expected, score B cancers, which had at least moderate staining, showed an intermediate outcome. Because cancers of score C that represent tumors with indistinct staining patterns (e.g. negative to weak expression of some and moderate to strong expression of other MMR genes) showed the same intermediate prognosis as score B, we combined these two groups (B/C) for further statistical analyses. Subset analysis in ERG-negative and ERG-positive cancers shows that all associations were strongly driven by the subset of ERGnegative cancers. In ERG-positive cancers, the prognostic value of the MMR genes was markedly attenuated or even absent. All data are summarized in Figure 3 . 
Relationship with other key genomic alterations in prostate cancers
Recent studies provided evidence for distinct molecular subgroups of prostate cancers defined by TMPRSS2-ERG fusions and genomic deletions. For example, deletions of PTEN and 3p are strongly linked to ERG-positive cancers, whereas deletions of 5q and 6q are associated with ERG negativity (21, 22, (25) (26) (27) . To search for associations between MMR gene alterations and genomic deletions, we compared MMR protein expression with existing data on these deletions from earlier analyses of our TMA. Up-regulation of MMR genesalone and in combination-was strongly linked to all analyzed deletions except 3p in the subset of ERG-negative cancers (PTEN: P < 0.0001, 6q: P < 0.0004, 5q: P < 0.0008). At least a strong trend was also found for 3p deletions where the lack of statistical significance was probably only due to the relatively small number of 3p-deleted cancers. No significant associations were found in ERG-positive cancers. All data are summarized in Figure 4 .
Relationship of MSH6, PMS2 and MLH1 expression with the deletion burden
To better understand the relationship between MSH6, PMS2 and MLH1 expression and the extent of deletions in prostate cancer, we combined copy number data obtained at five chromosome loci (3p, 6q, 5q, PTEN and TP53) and determined the number of deletions (minimum = 0, maximum = 5) in each cancer. Data on both the number of deletions at the five loci and the combined MSH6/PMS2/MLH1 expression groups were available from 2007 cancers. Comparison with the combined expression (MMR score) of the three analyzed MMR genes revealed a strong association between MMR gene upregulation and an increased deletion burden in ERG-negative (P = 0.0011; Figure 5A ), but not in ERG-positive cancers (P = 0.2416; Figure 5B ). 
Discussion
The results of our study demonstrate that high-level expression of MMR proteins parallels tumor aggressiveness and is linked to the features of disrupted genomic integrity in prostate cancer. Analysis of more than 11 000 prostate cancers and normal tissues in our TMA revealed that the MMR proteins MSH6, PMS2 and MLH1 frequently become up-regulated during cancer development. This is not unexpected, given that continuously dividing cancer cells are permanently challenged by DNA replication errors requiring active DNA repair (28) . Our findings are in line with earlier studies reporting up-regulation of PMS2 and MLH1 in 11-166 prostate cancers as compared with normal prostate glands (13, 16) . That comparable fractions of MMR protein overexpressing cancers (i.e. with moderate/strong staining) were described in these studies analyzing conventional large sections (52-69%), as well as in a TMA-based study on MLH1 (78%) (14) or in our TMA study (59-75%) , suggest that MMR protein up-regulation is a common feature of prostate cancers and also argues against extensive intratumoral heterogeneity of MMR gene expression. Increasing levels of all three analyzed MMR genes, alone or in combination, paralleled cancer aggressiveness including advanced tumor stage, high Gleason grade, lymph node metastasis and reduced time to biochemical recurrence in our study. This is in line with earlier studies reporting a link between high PMS2 expression and poor patient outcome in 101 and 166 prostate cancers (16, 29) . That such an association was not found in other studies (12) (13) (14) probably due to the limited number (n = 11-81) of the samples. In an own earlier study, we had found that more than 6000 cancers should optimally be analyzed to reproducibly identify molecular prognostic markers in prostate cancer (30 (38) . The extensive molecular database attached to our TMA allowed us to draw conclusions on the molecular mechanisms associated with MMR gene up-regulation. Structural genomic damage including gene fusions and genomic deletions is a hallmark of prostate cancer (39, 40) . The most frequent prostate cancer-specific gene fusion links the androgen-regulated gene TMPRSS2 with transcription factors of the ETS family (41), and large interstitial deletions including the PTEN locus and the chromosome arms 3p, 5q and 6q are frequently found in prostate cancers (20) (21) (22) 24) . Importantly, all these alterations result from erroneous repair of DNA double-strand breakage (DSB) (42) (43) (44) . The striking associations between increased MMR protein levels and ERG fusion, individual deletions and the overall deletion burden thus suggests that genomic damage triggers up-regulation of MMR genes. This is supported by recent work showing that MMR genes are involved in DSB repair (45) . For example, it has been shown that MLH1 modulates error-prone non-homologous end joining) DBS repair by inhibiting the annealing of DNA ends containing non-complementary base pairs (46) , and MSH6 was shown to up-regulate non-homologous end joining activity in vitro (47) . Also MSH2-the complex partner of MSH6-contributes to the removal of non-homologous ends in DSB-induced gene conversion (47, 48) . A potential causal link between genomic damage and MMR gene up-regulation could also explain their prognostic role, because genetic instability is associated with poor outcome in many tumor types including prostate cancer (49) (50) (51) (52) . Using the same TMA as in our current study, we earlier found that also overexpression of the DBS repair genes NBS1 (53) and LIG4 (54) is strongly linked to ERG fusion-type tumors, aggressive features and poor clinical outcome of prostate cancer. Although ERG fusion is the most frequent recurrent alteration in prostate cancer, affecting about 50% of tumors, ERG overexpression alone has no prognostic impact in hormone-naive prostate cancers (55) (56) (57) . Consequently, molecular tests aiming in the estimation of prostate cancer aggressiveness typically omit determination of the ERG status (58) (59) (60) . It is remarkable, however, that various proteins, such as the MMR genes, exert a prognostic role in only a subset of cancers defined by their ERG status. In our study, a positive ERG status appeared as a limitation for using MMR genes as prognostic markers. This was probably caused by the strong MMR gene up-regulation in ERG-positive cancers, appearing to overrule the effects of more prognostic alterations such as chromosomal deletions. As a consequence of the strong ERG-dependent up-regulation of MMR genes, all associations with adverse tumor features including highgrade, advanced stage and early biochemical recurrence were lost or at least massively reduced in the subset of ERG-positive cancers. That a clear-cut prognostic impact of MMR genes was found exclusively in ERG-negative cancers demonstrates the need for including ERG in potential molecular tests analyzing MMR genes as prognostic markers in prostate cancer. It is further noteworthy that our approach of analyzing molecular features on one very small tissue specimen per patient on a TMA measuring 0.6 mm in diameter represents a close model of molecularly analyzing core needle biopsies. Core needle biopsies enable the molecular analysis of comparable amounts of tissue as on a TMA. The optimal biomarker evaluation strategy would include the molecular analysis of the original needle biopsy of a patient and compare its prognostic value with pre-operative Gleason grade obtained on the same biopsy as well as the pre-operative PSA value. For practical purposes, this approach is not feasible because pre-operative biopsies are typically distributed over many different centers and not available for studies. Moreover, even if available, these precious core needle biopsies would be exhausted after only few studies. A convoluted approach evaluating multiple different scenarios mimicking both pre-and post-surgical situations was thus utilized in this study. Overall, our multivariate modeling suggests a prognostic relevance of MMR genes in ERG-negative prostate cancers that is independent of clinical and histopathological features available in a pre-operative scenario when only the biopsy Gleason grade, clinical stage and PSA value are available. In summary, our study shows that overexpression of MMR genes is a common feature of prostate cancers, which is linked to features of genetic instability, tumor aggressiveness and poor clinical outcome. The particularly strong up-regulation of these genes in ERG-positive cancers, however, limits their potential prognostic utility to the subset of ERG-negative cancers and highlights MMR genes as an example for molecular subtype-specific prognostic markers in prostate cancer.
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